Waycross Investment Management’s Danaher DHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$952K Sell
4,998
-80
-2% -$14.5K 0.72% 34
2026
Q1
$963K Sell
5,078
-53
-1% -$11.3K 0.92% 27
2025
Q4
$1.17M Sell
5,131
-164
-3% -$36.1K 1.03% 23
2025
Q3
$1.05M Sell
5,295
-174
-3% -$34.6K 1.07% 23
2025
Q2
$1.08M Sell
5,469
-218
-4% -$42.3K 1.12% 22
2025
Q1
$1.17M Sell
5,687
-5
-0.1% -$1.09K 1.31% 21
2024
Q4
$1.31M Sell
5,692
-69
-1% -$17K 1.38% 21
2024
Q3
$1.6M Sell
5,761
-635
-10% -$168K 1.48% 20
2024
Q2
$1.6M Sell
6,396
-64
-1% -$16.2K 1.54% 18
2024
Q1
$1.61M Buy
6,460
+349
+6% +$85.2K 1.5% 19
2023
Q4
$1.41M Sell
6,111
-869
-12% -$185K 1.56% 20
2023
Q3
$1.54M Hold
6,980
1.77% 14
2023
Q2
$1.49M Sell
6,980
-32
-0.5% -$6.77K 1.55% 15
2023
Q1
$1.57M Sell
7,012
-67
-0.9% -$15.2K 1.57% 13
2022
Q4
$1.67M Buy
+7,079
New +$1.64M 1.68% 11

Other funds holding DHR

Waycross Investment Management's DHR Position: Q2 2026 in Review

Waycross Investment Management reduced its Danaher (DHR) stake by 1.6% in Q2 2026, selling an estimated $14.5K and leaving 4,998 shares worth $952K. The position accounts for 0.72% of the portfolio, ranked #34.

Waycross Investment Management first reported a position in DHR in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.67M in Q4 2022. 607 funds tracked by Wall St. Rank hold DHR as of Q2 2026.

  • Waycross Investment Management held 4,998 shares of Danaher worth $952K as of Q2 2026.
  • Waycross Investment Management sold 80 Danaher shares in Q2 2026, an estimated $14.5K.
  • Danaher made up 0.72% of Waycross Investment Management's portfolio in Q2 2026, its #34 holding.
  • Waycross Investment Management first reported a position in Danaher in Q4 2022 and has held it in 15 quarters since.
  • Waycross Investment Management's Danaher position peaked at $1.67M in Q4 2022.
  • 607 funds tracked by Wall St. Rank held Danaher as of Q2 2026.

Based on Waycross Investment Management's 13F filing for Q2 2026, filed 14 Jul 2026.